Prevalence of Methicillin-resistant *Staphylococcus aureus* in Abeokuta, Nigeria

O. A. Osinupebi[1], J. A. Osiyemi[1*], A. M. Deji-Agboola[1], P. A. Akinduti[2] O. Ejilude[1], S. O. Makanjuola[1], N. O. Sunmola[1] and E. O. Osiyemi[1]

[1]*Department of Medical Microbiology and Parasitology, Olabisi Onabanjo University Teaching Hospital, Ogun State, Nigeria.*
[2]*College of Veterinary Medicine, Federal University of Agriculture, Alabata, Abeokuta, Nigeria.*

Authors' contributions

This work was carried out in collaboration between all authors. Author OAO designed the study and wrote the protocol. Author JAO carried out the practical work. Author AMDA managed the analyses of the study. Authors PAA, OE and SOM managed the literature searches. Authors NOS and EOO wrote the first draft of the manuscript. All authors read and approved the final manuscript.

Original Research Article

ABSTRACT

This study examined the prevalence of Methicillin-resistant *Staphylococcus aureus* (MRSA) in clinical samples of patients in Abeokuta, Ogun State, Nigeria using standard recommended procedures. A total of 338 clinical specimens of Pus, Aspirate, Ear and Wound swabs were collected from three major health facilities in Abeokuta, Nigeria. Each sample was cultured for bacteria isolates and examined for colonial and cellular morphology while biochemical identification was performed. Of the clinical samples collected, 50.3% were collected from male and highest rate of 37.9% was from age group 0-9 years and least rate of 7.6% was from age 10-19 and 40-49years. Only 32.9% samples were ear swabs, wound swabs (29.2%) and lowest rate of 16.8% for aspirate. Of the 161 *Staphylococcus aureus* (32.2%) isolated; there was no significant disparity found in relation to the study sites (χ^2=7.145, p-value = 0.308). The present study indicated a high prevalence rate of MRSA that require empirical and urgent intervention to prevent staphylococcal infection among the hospital patients and its outbreak.

___

Corresponding author: Email: osiyemijoshua@gmail.com;

1. INTRODUCTION

Staphylococcus aureus is a Gram-positive bacterium belonging to the family Staphylococcaceae and is often found as a commensal on the skin and mucous membranes particularly in the nose of healthy individuals [1]. It is a versatile human pathogen causing infections ranging from relatively mild skin and soft tissue infections to life-threatening sepsis, pneumonia, osteomyelitis, endocarditis as well as toxin-mediated syndromes such as toxic shock syndrome [2].

Staphylococcus aureus is able to cause a large diversity of both benign and lethal infections in humans and animals because of a wide range of virulence factors that include various toxins and enzymes [3]. It has emerged as one of the most important human pathogens and has become a leading cause of hospital and community-acquired infections [4].

Prior to the introduction of penicillin for the treatment of *S. aureus* infections in the 1940s, the mortality rate of individuals with staphylococcal infections was about 80% [5]. However within two years of the introduction of penicillin to medical use, penicillin-resistant strains were discovered. By 1960, about 80% of all *S. aureus* strains were found to be resistant to penicillin [6]. Methicillin was introduced in 1959 to treat infections caused by penicillin-resistant *S. aureus* but by 1961 there were reports of methicillin-resistant *S. aureus* from hospitals [7, 8].

Methicillin-resistant *Staphylococcus aureus* (MRSA) has been severally shown to cause a variety of diseases ranging from mild, superficial dermatological diseases to severe and potentially fatal systemic debilitations [9]. In spite of the availability of considerable number of effective antimicrobial chemotherapeutic agents, MRSA still remains an increasing cause of post-surgical wound infections and some invasive infections such as nosocomial sepsis, acute endocarditis and osteomyelitis, pneumonia and other soft tissue infections [10,11,12].

Methicillin resistant *Staphylococcus aureus* prevalence varies greatly with geographical location, type of hospital and studied population [13]. High prevalence has been recorded in tertiary hospitals in US, Southern European countries, Asia and South America [14]. In Africa, MRSA prevalence varies with different countries [15]. There are several studies on methicillin-resistant *Staphylococcus aureus* in Nigeria, particularly in Southwestern zone [16,17,18, 19,4]. This observation coupled with the threat posed by MRSA has led to the investigation of the prevalence in Abeokuta, Nigeria.

2. MATERIALS AND METHODS

2.1 Ethical Approval

Ethical approval was sought from the ethical committee of Federal Medical Centre, Abeokuta with REGISTRATION NUMBER: NHREC/08/10-2015.

2.2 Collection of Samples

A total of 338 clinical specimens consisting of wound swab, ear swab, aspirate and pus were collected from Medical Microbiology unit of Federal Medical Centre, Idi-Aba, Sacred Heart Hospital, Lantoro and Ogun State Management Board, Ijaiye, all in Abeokuta, Ogun State for the period of 6 months. The swab samples were collected using commercially prepared sterile swab sticks (Oxoid U.K.). They were kept refrigerated at 4°C until delivery, to the laboratory. All the samples where cultured immediately on appropriate media, within 12 hours of collection.

2.3 Isolation and Identification

The sterile culture media plates of Mannitol Salt agar (MSA), Mac Conkey agar (MCA), and Blood agar (BA) were dried in the oven to remove water of condensation in the plates as well as on the surface of the culture media. The swab samples were rubbed over one-quarter of each of the different agar plates (i.e. MSA, MCA and BA), the rest parts of the plates were streaked with a sterile wire loop to obtain discrete colonies. The inoculated culture media were incubated at 37^0C in an incubator for 24-48 hours. Suspected discrete colonies of *Staphylococcus aureus* were sub-cultured on Nutrient agar plates to obtain pure culture and for further analyses.

Each organism was identified according to Cowan and Steel [20] method of Bacteria identification, by their colonial appearances such

as size, shape, consistency, colour, elevation and its differential characteristics such as pigmentation, lactose fermentation on Mac Conkey and Gram staining was done to further identify the isolates.

2.4 Gram Staining Technique

A smear of the suspected colony from the culture plate was made on clean, grease-free glass slide. The smear was heat-fixed on slide by passing the slide over Bunsen burner flame briefly. The slide was then covered with Crystal violet stain and allowed to stain for one minute. The stain was decanted, rinsed with tap water and stained with Lugol's iodine for one minute. The stain was decanted and the film (smear) decolourized with acetone for few seconds. The slide was quickly washed with distilled water and counterstained with Safranin for one minute. The slide was finally washed with water, dried and examined under the microscope using the oil-immersion objective lens. Suspected *Staphylococcus aureus* isolates were Gram-positive cocci (appearing purples) and were arranged in clusters.

2.5 Biochemical Identification

Catalase Test: A drop of 3% hydrogen peroxide solution was placed on a clean, grease-free glass slide; the edge of another clean slide was used to pick the test organisms and was dipped into the hydrogen peroxide. Observed bubble formation was regarded positive.

Coagulase Test: Part of the colony was emulsified on a clean grease free glass slide. 10µl of citrated human plasma was added and was observed for the presence of agglutination which indicates a positive reaction.

Tube Coagulase Test: Isolates to be tested for Coagulase production were incubated in Mueller Hinton broth at 37°C for 24 hrs. 0.2 ml of the overnight broth culture was added to 0.5 ml citrated human plasma in a sterile glass test tube with gentle mixing; the test tubes were incubated at 37°C and observed for coagulation at the 1hr of 2 hrs, 4 hrs and 24 hrs. Formation of a firm opaque clot which remains in the place when the tube is tilted on its side was considered positive.

Mannitol Fermentation: Plates of Mannitol salt agar were prepared according to the manufacturer's directions allowed to cool at 50°C and poured in a sterile disposable plate to set.

The plates were labelled against the samples to be tested. The organism to be identified was inoculated on the set dried cooled plate with the aid of a sterile wire loop (streaking), Incubated at 37°C for 18hrs and was checked for evidence of growth on the agar surface and as well for a colour change from red to golden yellow. Mannitol salt agar enables us to determine the different characteristics. The first is the organism ability to tolerate a high salt concentration environment which was indicated by the evidence of growth on the mannitol salt plate. Secondly, fermentation of the sugar mannitol by producing an acid, an end product which changes the red pH indicator in the medium to yellow. Change from red to yellow colour was considered positive.

2.6 Antimicrobial Sensitivity Testing

The susceptibility of isolates to various antibiotics was determined according to Bauer et al.[21] and Clinical laboratory Standard Institute [22] modified disc diffusion technique [23]. Inoculum was prepared by touching a colony of the test organism with a sterile wire loop and the growth transferred into a Bijou bottle containing Mueller Hinton Broth. The cell suspensions were incubated for 2 hours and the bacterial suspension adjusted to 0.5 McFarland's standard using Mueller Hinton Broth. Mueller Hinton agar plates were dried in the hot-air oven by inverting petri dishes containing the media to remove surface moisture. Plates were then inoculated within 15 minutes of preparation of the suspension. A sterile cotton swab was dipped into the suspension of isolate and excess fluid was removed by rotation of the swab against the side of the bottles above the fluid level. The agar plates were then inoculated by even streaking of the swab over the entire surface of the plate in three directions at 60° to each other. The plates were left for 10 to 15 minutes on the laboratory bench before single antibiotic discs were aseptically placed using the Antibiotic disc dispenser. Plates were incubated at 37°C for 18 to 24 hours. Growth inhibition was shown as circular zone of no growth around the disc. The diameter of the zone of inhibition was measured using a graduated ruler and result interpreted according to Clinical Laboratory Standard Institute [22].

2.7 Methicillin-resistance Screening

Isolates were screened for methicillin resistance using the method of Markowitz et al. [24].

Staphylococcus aureus was inoculated into Mueller Hinton Broth (MHB) and was incubated at 37°C overnight. A suspension of the inoculum which is equivalent to 0.5 McFarland Standard was streaked on Mueller Hinton agar (MHA) with 4% NaCl. Cefoxitin (30µg) was aseptically placed on the inoculated plate and the plate was incubated for 18 hours at 35°C. The isolate with an inhibition zone of ≤21mm was considered Methicillin resistant *Staphylococcus aureus* (MRSA) Strain. *Staphylococcus aureus* ATCC 25923 was used as a Control.

3. RESULTS

Out of the 500 bacterial isolates obtained from 338 clinical specimens from Federal Medical Centre, Idi-Aba, Sacred Heart Hospital, Lantoro and Ogun State Hospital, Ijaiye; 161 (32.2%) were identified by biochemical reactions to be *Staphylococcus aureus* as shown in Fig. 1. Out of these samples, 14.9% were recovered from Aspirate, 20.5% Pus, 29.8% and 34.8% from Ear and wound swabs respectively (Fig. 2).

Table 1 shows that there was no significant disparity found in the distribution of *Staphylococcus aureus* in relation to the sample type (χ^2=7.145, p-value = 0.308). Also, out of the 161 *Staphylococcus aureus*, 81 (50.3%) were observed from males while 80 (49.7%) from females were observed in the study.

The susceptibility pattern of *Staphylococcus aureus* to different antibiotics is shown in Table 2. Majority of the Methicillin resistant *Staphylococcus aureus* (MRSA) were resistant to other antibiotics such as Cotrimoxazole (93.9%), Tetracycline (89.4%), Augmentin (72.7%), Erythromycin (71.2%), etc. The result of the association between MRSA and MSSA with gender vividly reveals that there was no significant statistical difference as observed in Table 3 (χ^2 = 0.004, p-value = 0.538).

Distribution of MRSA in relation to the age of patients revealed that age group 0-9 (36.4%) had the highest prevalence of MRSA when compared with age group 70-79 (3.0%) having the least as shown in Table 4.


**Fig. 1. Distribution of bacterial isolates from clinical samples in Abeokuta**

Fig. 2. Distribution of *Staphylococcus aureus* in Clinical specimens obtained from different health facilities in Abeokuta

Table 1. Distribution of *Staphylococcus aureus* in clinical specimens in relation to Study sites

Clinical Specimens	Health facilities (%)	χ^2	P-value
Ear Swab	48 (29.8)		
Wound Swab	56 (34.8)	7.145	0.308
Pus	33 (20.5)		
Aspirate	24 (14.9)		

Table 2. Susceptibility Patterns of *Staphylococcus aureus* isolated from Clinical Specimens in Abeokuta

Antibiotics	Susceptible Number (%)	Intermediate Number (%)	Resistant Number (%)
Tetracycline	39 (24.2)	13 (8.1)	109 (67.7)
Ciprofloxacin	76 (47.2)	44 (27.3)	41 (25.5)
Gentamicin	82 (50.9)	38 (23.6)	41 (25.5)
Augumentin	92 (57.1)	0 (0.0)	69 (42.9)
Cotrimoxazole	21 (13.0)	14 (8.7)	126 (78.3)
Ofloxacin	73 (45.3)	38 (23.6)	50 (31.1)
Cefoxitin	95 (59.0)	0 (0.0)	66 (41.0)
Erythromycin	83 (51.6)	19 (11.8)	59 (36.6)
Ceftazidime	73 (45.3)	44 (27.3)	44 (27.3)
Ceftriaxone	71 (44.1)	51 (31.7)	39 (24.2)
Vancomycin	98 (60.9)	37 (23.0)	26 (16.1)
Linezolid	125 (77.6)	0 (0.0)	36 (22.4)

Table 3. Association of methicillin resistant *Staphylococcus aureus* (MRSA) and methicillin susceptible *Staphylococcus aureus* (MSSA) in relation to gender

	Female	Male	χ^2	P-value
MSSA	47 (49.5)	48 (50.5)	0.004	0.538
MRSA	33 (50.0)	33 (50.0)		

Table 4. Association of methicillin resistant *Staphylococcus aureus* (MRSA) and methicillin susceptible *Staphylococcus aureus* (MSSA) in relation to age groups

Age groups	MSSA	MRSA	χ^2	P-value
0-9	25 (26.3)	24 (36.4)		
10-19	14 (14.7)	5 (7.6)		
20-29	14 (14.7)	14 (21.2)		
30-39	6 (6.3)	7 (10.6)	7.833	0.348
40-49	14 (14.7)	5 (7.6)		
50-59	13 (13.7)	6 (9.1)		
60-69	7 (7.4)	3 (4.5)		
70-79	2 (2.2)	2 (3.0)		
Total	95 (100)	66 (100)		

4. DISCUSSION

Methicillin-resistant *Staphylococcus aureus* (MRSA) is a serious threat to hospitalized patients globally and it now represents a challenge for public health; as community-associated infections appear to be on the increase in both adults and children in various regions and countries [25]. A number of investigations have reported *Staphylococcus aureus* among the most frequently encountered bacteria species in Microbiology laboratory in Nigeria [26].

This study was aimed at determining the prevalence of MRSA infections in Abeokuta as well as determining the antibiotic resistance indices of MRSA from different clinical specimens in Abeokuta. In this study, prevalence of MRSA was 41%. This is in agreement with a report carried out by Ikeh [27] in Jos, Nigeria that reported a rate of 43.0% prevalence of MRSA; likewise, the result obtained is in concordance with a report from Oshogbo, Nigeria that recorded a prevalence rate of 47.8% [28]. Although this prevalence was higher than 20.3% reported by Ghebremedhin et al. [18] in Ibadan; 12.5% reported by Okon et al. [29] in Maiduguri, and Taiwo et al. [30] in Ilorin (34.7%).

The different Prevalence results obtained from several studies indicated that the prevalence of the MRSA varies from one Geographical location to another. It is clear that MRSA has become a

5

Global nosocomial pathogen with attendant therapeutic problems and warrant urgent infection awareness, considering the common practice of unregulated sale of an antimicrobial agent [31,32,29].

Though MRSA does not show a predilection for any particular age or sex, no age is exempt from these infections. In the present study, it was found that highest rate of MRSA was observed in age group of 0-9 years showing a prevalence rate of 36.4% while age group 70-79 had the least prevalence of MRSA with 3.0%. This age group comprises of neonates, toddlers and pre-school children who were highly predisposed to various Staphylococcal infections from contaminated food materials, toys and fingers [33]. Moreover, higher incidence of MRSA infections among males has also been reported by Chua et al. [34] which do not correlate with our findings that show 50% for both male and female.

5. CONCLUSION

In this study, the prevalence of MRSA is considerably high to warrant urgent infection awareness. The high resistance to the β-lactam antibiotics used in this study shows that these agents are becoming ineffective in the treatment. Also, there is need to reassess policies on antibiotic use within the hospital environment. However, a major limitation to this study was the inability to identify Panton-Valentine Leukocidin-positive isolates, as this would have revealed the level of potential public health *Staphylococcus aureus* poses to the general population of Abeokuta, Nigeria.

6. RECOMMENDATIONS

Since the complete eradication of MRSA may not be possible, control of transmission seems to be the appropriate goal. The efficacy of some controlling methods are widely recognized and recommended by most authors. The first and the most effective way among these are to avoid transmission through hand contamination from personnel even to patients.

The use of broad-spectrum antibiotics for treating infections also increases the rate of MRSA and other resistant bacteria. Therefore chemotherapy should be guided by sensitivity of the probable causative organism. Accurate detection of MRSA by clinical laboratories is of great importance; also awareness should be created about the route of its transmission in the community and the risk factors for infection such as antimicrobial and parental drug use.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Plata K, Rosato AE, Wegrzyn G. *Staphylococcus aureus* as an infectious agent: overview of biochemistry and molecular genetics of its pathogenicity. Acta Biochimica Polonica. 2009;56:597–612.
2. Shittu AO, Okon K, Adesida S, Oyedara O, Witte W, Strommenger B, Layer F, Nübe U. Antibiotic resistance and molecular epidemiology of *Staphylococcus aureus* in Nigeria. BioMedical Central of Microbiology. 2011;11:92-94.
3. Bal AM, Gould IM. Antibiotic resistance in *Staphylococcus aureus* and itsrelevance in therapy. Expert. Opinion on Pharmacotherapy. 2005;6(13):2257-2269.
4. Shittu AO, Lin J. Antimicrobial susceptibility patterns and characterization of clinical isolates of *Staphylococcus aureus* in KwaZulu-Natal province, South Africa. BioMedical Central of Infectious Disease. 2006;6(1):125.
5. Skinner D, Keefer CS. Significance of bacteremia caused by *Staphylococcus aureus.* Archives of Internal Medicine. 1941;68:851-875.
6. Deurenberg RH, Stobberingh EE. The evolution of *Staphylococcus aureus.*Infection, Genetic and Evolution. 2008;8(6):747-763.
7. Barrett F, McGehee R, Finland M. Methicillin-resistant *Staphylococcus aureus* at Boston city hospital. New England. Journal of Medicine. 1968;278:441-448.
8. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin resistant *Staphylococcus aureus* (MRSA). Proceedings of the National Academy of Sciences. 2002;99(11):7687–7692.
9. Moran GJ, Amii RN, Abrahaman FM, Talan DA. Methicillin – resistant *Staphylococcus aureus* in community acquired skin infections – Emerging infectious Disease. 2005;11(11):928-930.

10. Gottilebs GS, Fowler VG Jr. and Kong IK. *Staphylococcus aureus* bacteremia in the surgical patients a prospective analysis of 73 post opernative patients who developed *staphylococcus aureus* bactermia at a tertiary care facility. Journal of Annals of the Royal College of surgeons of England. 2000;190:50-57.

11. Grafunder EM, Veriezia RA. Risk factors associated with nosocomial methicillin – resistant *Staphylococcus aureus* (MRSA) infection including previous use of antimicrobial. Journal of Antimicrobial chemotherapy. 2002;49:999-1005.

12. Rello J, Diaz E. Pneumonia in the intensive care unit. Critical Care Medicine. 2003; 37: 2544-2551.

13. Adetayo TO, Deji-Agboola AM, Popoola MY, Atoyebi TJ, Egberongbe KJ. Prevalence of methicillin resistant *Staphylococcus aureus* from clinical specimens in Ibadan, Nigeria. The international Journal of Engineering and Science.2014;3(6):1-11.

14. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, Beach M. Survey of infections due to *Staphylococcus species:* frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program. 1997–1999. Clinical Infectious Disease. 2001; 32(2):114–132.

15. Bell JM, Turnidge JD. High prevalence of oxacillin-resistant *Staphylococcus aureus* isolates from hospitalized patients in Asia-Pacific and South Africa: results from SENTRY antimicrobial surveillance program, 1998–1999. Antimicrobial Agents and Chemotherapy. 2002;46:879–881.

16. Adeleke SI, Asani MO. Urinary tract infection in children with nephritic syndrome in Kano, Nigeria. Annals of African Medicine. 2009;8:38-41.

17. Adesida SA, Boelens H, Babajide B, Kehinde A, Snijders S, van Leeuwen W, Coker A, Verbrugh H, van Belkum A. Major epidemic clones of *Staphylococcus aureus* in Nigeria. Microbial Drug Resistance. 2005;11:115-121.

18. Ghebremedhin B, Olugbosi MO, Raji AM, Layer F, Bakare RA, Konig B, Konig W. Emergence of a Community- Associated Methicillin-Resistant *Staphylococcus aureus* Strain with a Unique Resistance Profile in Southwest Nigeria. Journal of Clinical Microbiology. 2009;47:2975-2980.

19. Onipede AO, Onayade AA, Elusiyan JB, Obiajunwa PO, Ogundare OO, Olaniran OO, Adeyemi LA, Oyelami OO. Invasive bacteria isolates from children with severe infections in a Nigerian hospital. Journal of Infection in Developing Countries.2009; 3(6):429-436.

20. Cowan and Steel Manual for the Identification of Modified Bacteria. Cambridge University Press Third Edition; 2003.

21. Bauer AW, Kirby WM, Sherries JC, Turk M. Antibiotic susceptibility testing by a standard single disc methods. American Journal of Clinical Pathology. 1996;45:493-496.

22. CLSI. M100-S25 performance standards for antimicrobial susceptibility testing; Twenty-fifth informational supplement. 2015;35(3):60-70.

23. Cheesbrough M. District Laboratory Practices Manual in Tropical Countries Part 2. Cambridge University Press, Cambridge. 2000;178-179.

24. Markowitz N, Pohlod DJ, Saravolatz LD, Quinn EL. *In-vitro* susceptibility of methicillin-resistant and susceptible *Staphylococcus aureus* strains in population of Bacterial drug abusers from 1972-1981. Antimicrobial Agents and Chemotherapy. 1983;23:450-457.

25. Layton MC, Hierholzer WJ, Patterson JE. The evolving epidemiology of methicillin-resistant *Staphylococcus aureus* at a university hospital. Infectious Control Hospital Epidemiology. 1995;16:12-17.

26. Ambe JP, Gasi IS, Mava Y. Review of Neonatal infections in University of Maiduguri Teaching Hospital: Common Bacteria seen. Nigerian Journal of Clinical Practice. 2007;10:290-293.

27. Ikeh EI. Methicillin – Resistant *Staphylococcus aureus* (MRSA) at Jos teaching hospital. African Journal of Clinical and Experimental Microbiology. 2003;4(1):52-55.

28. Olowe OA, Eniola KI, Olowe RA, Olayemi AB. Antimicrobial susceptibility and Beta-lactamase detection of MRSA in Oshogho South West, Nigeria. Nature and Science. 2007;5(3):44-48.

29. Okon KO, Basset A, Uba P, Oyawoye OM, Yusuf ZI, Shittu AO, Blanc J. Epidemiology

and characteristic pattern of Methicillin-Resistance *Staphylococcus aureus* Recovered from Tertiary Hospital in Northeastern, Nigeria. International Journal of Tropical Medicine. 2011;6(5): 106-112.

30. Taiwo SS, Onile BA, Akanbi AA. Methicillin-resistant *Staphylococcus aureus* (MRSA) isolates in Nigeria. African Journal of Clinical and Experimental Microbiology. 2004;5(2):189-197.

31. Akinduti PA, Oluwadun A, Iwalokun BA, Oluwaseun E, Onagbesan KO. Clonal dissemination of bla TEM β-Lactamase strains among enteric isolates in Abeokuta, Nigeria. Research Journal of Microbiology. 2011;6:919-925.

32. Holloway K. Antimicrobial resistance: the facts. Essential Drug Monitor WHO. 2000; 29:7–8.

33. Milstone AM, Goldner BW, Ross T, Shepard JW, Carroll KC, Perl TM. Methicillin-resistant *Staphylococcus aureus* colonization and the risk of subsequent infection in critically ill children; importance of preventing nosocomial methicillin-resistant Staphylococcus aureus transmission. Clinical infectious Diseases. 201153(9):853-859.

34. Chua T, Moore CL, Perri MB, Donabedian SM, Masch W. Molecular epidemiology of methicillin-resistant *Staphylococcus aureus* bloodstream isolates in urban Detroit. Journal of Clinical Microbiology. 2008; 46:2345-2352.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sciencedomain.org/review-history/23702